SMS Pharmaceuticals Limited — Updates, 30-05-2025: Press Release

SMS Pharmaceuticals has announced a board meeting to review the financial results for the quarter and half-year. The USFDA completed its inspection of SMS’s Hyderabad API facility, identifying one procedural observation that was quickly addressed. The 120 KL-capacity plant, approved by multiple global regulators, strengthens SMS Pharma’s manufacturing base and supports expansion in key international markets, enhancing investor confidence in its operational and compliance standards.